Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-04-20

Clinical Trial Update: Pembrolizumab in High-risk Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for pembrolizumab in high-risk differentiated thyroid cancer; study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Istituti Clinici Scientifici Maugeri SpA | Conditions: Differentiated Thyroid Cancer | Phase 2 | Status: RECRUITING